4D Molecular Therapeutics, Inc.
FDMT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650648
In the last 90 days, 4D Molecular Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 157 institutions reported holding it in 13F filings for Q2 2026, worth $771.2M in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.74M in total
- 7
- 13F holdersQ2 2026, +6 vs. previous quarter
- 157
- 13F valueReported value at the end of Q2 2026
- $771.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $85.2M
- +230,194.6% year over year
- Net income, FY2025
- -$140.1M
- No comparable prior period
- Free cash flow, FY2025
- -$109.6M
- No comparable prior period
- Revenue, Q2 FY2026
- $3.78M
- +25,106.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $140.1M (164.4% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.9M
- Shares sold short
- Change
- −632.7K
- −5.5% vs. previous
- Days to cover
- 10.43
- At average daily volume
Superinvestors holding FDMT, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding FDMT at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by 4D Molecular Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2026 (view filing)4:56 PM ET | Oct 16 | 4 days | Bizily ScottChief Legal Officer | SSale | −1.64K | $12.84 | −$21.0K | −15.9%8.62K after | 10b5-1 |
| Oct 7, 2026 (view filing)5:11 PM ET | Oct 5 | 2 days | Kirn DavidSee Remarks | SSale | −58.3K | $12.92 | −$753.9K | −7.6%709.2K after | 2 lots10b5-1 |
| Sep 22, 2026 (view filing)6:43 PM ET | Sep 16 | 6 daysLate | Bizily ScottChief Legal Officer | SSale | −1.64K | $13.65 | −$22.3K | −15.9%8.62K after | 10b5-1 |
| Sep 16, 2026 (view filing)5:13 PM ET | Sep 14 | 2 days | Kirn DavidSee Remarks | SSale | −58.3K | $13.90 | −$811.0K | −7.1%767.5K after | 10b5-1 |
| Sep 3, 2026 (view filing)6:55 PM ET | Sep 1 | 2 days | Bizily ScottChief Legal Officer | SSale | −584 | $14.00 | −$8.18K | −6.3%8.62K after | 10b5-1 |
| Aug 21, 2026 (view filing)4:06 PM ET | Aug 19 | 2 days | Kirn DavidSee Remarks | SSale | −69.1K | $15.75 | −$1.09M | −7.7%825.8K after | 2 lots10b5-1 |
| Aug 17, 2026 (view filing)5:34 PM ET | Aug 13-17 | 4 days | Bizily ScottChief Legal Officer | SSale | −3.27K | $12.10 | −$39.6K | −27.5%8.62K after | 2 lots10b5-1 |
| Aug 5, 2026 (view filing)4:10 PM ET | Aug 4 | 1 day | Kirn DavidSee Remarks | SSale | −26.8K | $10.23 | −$274.6K | −3.1%844.9K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:45 PM ET | Aug 3 | 1 day | Kirn DavidSee Remarks | SSale | −12.4K | $10.05 | −$124.7K | −1.4%871.7K after | 10b5-1 |
| Jul 14, 2026 (view filing)5:04 PM ET | Jul 9-10 | 5 daysLate | Kirn DavidSee Remarks | SSale | −58.3K | $12.64 | −$737.4K | −6.2%884.2K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 157 holdersThe largest institutional positions in 4D Molecular Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 5,746,289 | $76.5M | 0.03% | +5,746,289 | New |
| Ra Capital Management, L.P. | 5,049,779 | $67.2M | 0.58% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,546,059 | $60.5M | 0.00% | +400,756+9.7% | Added |
| Goldman Sachs Group Inc | 4,258,668 | $56.6M | 0.01% | +53,230+1.3% | Added |
| Novo Holdings A/S | 3,249,178 | $43.2M | 2.52% | −401,559−11.0% | Reduced |
| State Street Corp | 2,911,109 | $38.7M | 0.00% | +203,234+7.5% | Added |
| BVF Inc | 2,879,289 | $38.3M | 0.98% | 00.0% | Unchanged |
| T. Rowe Price Investment Management, Inc. | 2,511,887 | $33.4M | 0.02% | +2,511,887 | New |
| Adage Capital Partners GP, L.L.C. | 2,249,203 | $29.9M | 0.04% | +644,047+40.1% | Added |
| Trails Edge Capital Partners, LP | 2,227,917 | $29.6M | 4.70% | +925,000+71.0% | Added |
Holders of 5% or more of FDMT
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of 4D Molecular Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Janus Henderson Group PLC | 13G/A | 10.30%5.25M shares | +2.20 ppfrom 8.10% | Feb 11, 20227 filings | Apr 7, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 9.99%5.35M shares | 0.00 ppfrom 9.99% | Jul 6, 20218 filings | May 15, 2026 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%5.11M shares | 0.00 ppfrom 9.90% | Jun 5, 20237 filings | May 15, 2026 | SEC |
| Goldman Sachs Group Inc | 13G/A | 7.50%4.29M shares | −2.10 ppfrom 9.60% | Nov 6, 20243 filings | Feb 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.60%3.06M shares | −1.20 ppfrom 7.80% | Oct 21, 20245 filings | Oct 17, 2025 | SEC |